Serum NGAL is Associated with Distinct Plasma Amyloid-β Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome

Journal of Alzheimer's Disease

Volumn 45, Issue 3, 2015, Pages 733-743

  Naudé, Petrus J W ^a,b   Dekker, Alain D ^a,c   Coppus, Antonia M W ^d,e,f   Vermeiren, Yannick ^c   Eisel, Ulrich L M ^a,b   Van Duijn, Cornelia M ^e   Van Dam, Debby ^c   De Deyn, Peter P ^a,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d Center for the Intellectually Disabled   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; amyloid ; apolipoprotein E; biomarker; down syndrome; inflammation; lipocalin 2; platelets

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ACUTE PHASE PROTEIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

AGED; ALLELE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMENTIA; DOWN SYNDROME; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; BLOOD; COMPLICATION; LONGITUDINAL STUDY; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; VERY ELDERLY;

ACUTE-PHASE PROTEINS; AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; DEMENTIA; DOWN SYNDROME; FEMALE; HUMANS; LIPOCALINS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; PSYCHIATRIC STATUS RATING SCALES;

EID: 84925778446     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142514     Document Type: Article

References (62)

1. Shin M, Besser LM, Kucik JE, Lu C, Siffel C, Correa A, Congenital Anomaly Multistate Prevalence and Survival Collaborative (2009) Prevalence of Down syndrome among children and adolescents in 10 regions of the United States. Pediatrics 124, 1565-1571.
2. Presson AP, Partyka G, Jensen KM, Devine OJ, Rasmussen SA, McCabe LL, McCabe ER (2013) Current estimate of Down syndrome population prevalence in the United States. J Pediatr 163, 1163-1168.
3. Yang Q, Rasmussen SA, Friedman JM (2002) Mortality associated with Down's syndrome in the USA from 1983 to 1997: A population-based study. Lancet 359, 1019-1025.
4. Webb RL, Murphy MP (2012) beta-Secretases, Alzheimer's disease, and Down syndrome. Curr Gerontol Geriatr Res 2012, 362839.
5. Zigman WB, Lott IT (2007) Alzheimer's disease in Down syndrome: Neurobiology and risk. Ment Retard Dev Disabil Res Rev 13, 237-246.
6. Mann DM (1988) Alzheimer's disease and Down's syndrome. Histopathology 13, 125-137.
7. Tokuda T, Fukushima T, Ikeda S, Sekijima Y, Shoji S, Yanagisawa N, Tamaoka A (1997) Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome. Ann Neurol 41, 271-273.
8. Mehta PD, Dalton AJ, Mehta SP, Kim KS, Sersen EA, Wisniewski HM (1998) Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett 241, 13-16.
9. Schupf N, Patel B, Silverman W, Zigman WB, Zhong N, Tycko B, Mehta PD, Mayeux R (2001) Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 301, 199-203.
10. Wilcock DM (2012) Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease. Curr Gerontol Geriatr Res 2012, 170276.
11. Wilcock DM, Griffin WS (2013) Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J Neuroinflammation 10, 84.
12. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, 3rd, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86, 7611-7615.
13. Rodrigues R, Debom G, Soares F, Machado C, Pureza J, Peres W, de Lima Garcias G, Duarte MF, Schetinger MR, Stefanello F, Braganhol E, Spanevello R (2014) Alterations of ectonucleotidases and acetylcholinesterase activities in lymphocytes of Down syndrome subjects: Relation with inflammatory parameters. Clin Chim Acta 433, 105-110.
14. Trotta MB, Serro Azul JB, Wajngarten M, Fonseca SG, Goldberg AC, Kalil JE (2011) Inflammatory and Immunological parameters in adults with Down syndrome. Immun Ageing 8, 4.
15. Nateghi Rostami M, Douraghi M, Miramin Mohammadi A, Nikmanesh B (2012) Altered serum pro-inflammatory cytokines in children with Down's syndrome. Eur Cytokine Netw 23, 64-67.
16. Naudé PJW, Nyakas C, Eiden LE, Ait-Ali D, Heide Rvd, Engelborghs S, Luiten PGM, De Deyn PP, den Boer JA, Eisel ULM (2012) Lipocalin 2: Novel component of proinflammatory signaling in Alzheimer's disease. FASEB J 26, 2811.
17. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268, 10425-10432.
18. Choi J, Lee H-W, Suk K (2011) Increased plasma levels of lipocalin 2 in mild cognitive impairment. J Neurol Sci 305, 28-33.
19. Naudé PJ, Eisel UL, Comijs HC, Groenewold NA, De Deyn PP, Bosker FJ, Luiten PG, den Boer JA, Oude Voshaar RC (2013) Neutrophil gelatinase-associated lipocalin: A novel inflammatory marker associated with late-life depression. J Psychosom Res 75, 444-450.
20. Naudé PJW, den Boer JA, Comijs HC, Bosker FJ, Zuidersma M, Groenewold NA, De Deyn PP, Luiten PGM, Eisel ULM, Oude Voshaar RC (2014) Sex-specific associations between Neutrophil Gelatinase-Associated Lipocalin (NGAL) and cognitive domains in late-life depression. Psychoneuroendocrinology 48, 169-177.
21. Dogliotti G, Galliera E, Licastro F, Porcellini E, Corsi MM (2010) Serum neutrophil gelatinase-B associated lipocalin (NGAL) levels in Down's syndrome patients. Immun Ageing 7 Suppl 1, S7.
22. Mesquita SD, Ferreira AC, Falcao AM, Sousa JC, Oliveira TG, Correia-Neves M, Sousa N, Marques F, Palha JA (2014) Lipocalin 2 modulates the cellular response to amyloid beta. Cell Death Differ 21, 1588-1599.
23. Paratore S, Parenti R, Torrisi A, Copani A, Cicirata F, Cavallaro S (2006) Genomic profiling of cortical neurons following exposure to beta-amyloid. Genomics 88, 468-479.
24. Dekker AD, Coppus AM, Vermeiren Y, Aerts T, van Duijn CM, Kremer BP, Naude PJ, Van Dam D, De Deyn PP (2014) Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome. J Alzheimers Dis 43, 871-891.
25. Coppus AMW, Evenhuis HM, Verberne GJ, Visser FE, Arias-Vasquez A, Sayed-Tabatabaei FA, Vergeer-Drop J, Eikelenboom P, van Gool WA, van Duijn CM (2008) The impact of apolipoprotein E on dementia in persons with Down's syndrome. Neurobiol Aging 29, 828-835.
26. Coppus AMW, Schuur M, Vergeer J, Janssens ACJW, Oostra BA, Verbeek MM, van Duijn CM (2012) Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome. Neurobiol Aging 33, 1988-1994.
27. Coppus AM, Evenhuis HM, Verberne GJ, Visser FE, Arias-Vasquez A, Sayed-Tabatabaei FA, Vergeer-Drop J, Eikelenboom P, van Gool WA, van Duijn CM (2008) The impact of apolipoprotein E on dementia in persons with Down's syndrome. Neurobiol Aging 29, 828-835.
28. Coppus A, Evenhuis H, Verberne GJ, Visser F, van Gool P, Eikelenboom P, van Duijin C (2006) Dementia and mortality in persons with Down's syndrome. J Intellect Disabil Res 50, 768-777.
29. th revision, http://www.who.int/classifications/icd/en/
30. Aylward EH, Burt DB, Thorpe LU, Lai F, Dalton A (1997) Diagnosis of dementia in individuals with intellectual disability. J Intellect Disabil Res 41(Pt 2), 152-164.
31. Burt DB, Aylward EH (2000) Test battery for the diagnosis of dementia in individuals with intellectual disability. Working Group for the Establishment of Criteria for the Diagnosis of Dementia in Individuals with Intellectual Disability. J Intellect Disabil Res 44(Pt 2), 175-180.
32. Holland AJ, Hon J, Huppert FA, Stevens F, Watson P (1998) Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome. Br J Psychiatry 172, 493-498.
33. Strydom A, Chan T, Fenton C, Jamieson-Craig R, Livingston G, Hassiotis A (2013)Validity of criteria for dementia in older people with intellectual disability. Am J Geriatr Psychiatry 21, 279-288.
34. Evenhuis HM, Kengen MMF, Eurlings HAL (1998) Dementie Vragenlijst voor Verstandelijk Gehandicapten (DVZ), Harcourt Test Publishers, Amsterdam.
35. Kraijer DW, Kema GN, de Bildt AA (2004) Sociale Redzaamheidsschaal voor Verstandelijk Gehandicapten (SRZ/SRZI), Handleiding Harcourt Test Publishers.
36. Sparrow SS (1984) Vineland Adaptive Behaviour Scales, Interview Edition, Expanded form manual. American.
37. Zhao SJ, Guo CN, Wang MQ, Chen WJ, Zhao YB (2012) Serum levels of inflammation factors and cognitive performance in amnestic mild cognitive impairment: A Chinese clinical study. Cytokine 57, 221-225.
38. Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR Jr, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM (2011) Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 122, 401-413.
39. Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 5, 18-29.
40. Chen M, Inestrosa NC, Ross GS, Fernandez HL (1995) Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 213, 96-103.
41. Durand CP (2013) Does raising type 1 error rate improve power to detect interactions in linear regression models? A simulation study. PLoS One 8, e71079.
42. Olgiati P, Politis A, Malitas P, Albani D, Dusi S, Polito L, De Mauro S, Zisaki A, Piperi C, Stamouli E, Mailis A, Batelli S, Forloni G, De Ronchi D, Kalofoutis A, Liappas I, Serretti A (2010) APOE epsilon-4 allele and cytokine production in Alzheimer's disease. Int J Geriatr Psychiatry 25, 338-344.
43. Chakraborty S, Kaur S, Guha S, Batra SK (2012) The multi-faceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 1826, 129-169.
44. Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, Tolan DR, Selkoe DJ, Lemere CA (2002) Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 9, 88-102.
45. Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y (1995) Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol 37, 294-299.
46. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezzini P, Bertolini S, Mann DM, Tabaton M, Gambetti P (1996) Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2, 93-95.
47. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ (1996) Sequence of deposition of heterogeneous amyloid β-peptides and APO E in Down syndrome: Implications for initial events in amyloid plaque formation. Neurobiol Dis 3, 16-32.
48. Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17, 278-282.
49. Mann DM, Esiri MM (1989) The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 89, 169-179.
50. Dekker AD, De Deyn PP, Rots MG (2014) Epigenetics: The neglected key to minimize learning and memory deficits in Down syndrome. Neurosci Biobehav Rev 45, 72-84.
51. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3, 75-80.
52. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F (2012) Plasma amyloid-β as a predictor of dementia and cognitive decline:Asystematic reviewand meta-analysis. Arch Neurol 69, 824-831.
53. Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC (2001) Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125, 489-492.
54. Perlmutter LS, Scott SA, Barron E, Chui HC (1992) MHC class II-positive microglia in human brain: Association with Alzheimer lesions. J Neurosci Res 33, 549-558.
55. Russo C, Saido TC, DeBusk LM, Tabaton M, Gambetti P, Teller JK (1997) Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett 409, 411-416.
56. Lee S, Park JY, Lee WH, Kim H, Park HC, Mori K, Suk K (2009) Lipocalin-2 is an autocrine mediator of reactive astrocytosis. J Neurosci 29, 234-249.
57. Jang E, Kim JH, Lee S, Kim JH, Seo JW, Jin M, Lee MG, Jang IS, Lee WH, Suk K (2013) Phenotypic polarization of activated astrocytes: The critical role of lipocalin-2 in the classical inflammatory activation of astrocytes. J Immunol 191, 5204-5219.
58. Jang E, Lee S, Kim JH, Kim JH, Seo JW, Lee WH, Mori K, Nakao K, Suk K (2013) Secreted protein lipocalin-2 promotes microglial M1 polarization. FASEB J 27, 1176-1190.
59. Jin M, Kim JH, Jang E, Lee YM, Soo Han H, Woo DK, Park DH, Kook H, Suk K (2014) Lipocalin-2 deficiency attenuates neuroinflammation and brain injury after transient middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 34, 1306-1314.
60. Rathore KI, Berard JL, Redensek A, Chierzi S, Lopez-Vales R, Santos M, Akira S, David S (2011) Lipocalin 2 plays an immunomodulatory role and has detrimental effects after spinal cord injury. J Neurosci 31, 13412-13419.
61. Toledo JB, Shaw LM, Trojanowski JQ (2013) Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. Alzheimers Res Ther 5, 8.
62. Pedersen KR, Ravn HB, Hjortdal VE, Norregaard R, Povlsen JV (2010) Neutrophil gelatinase-associated lipocalin (NGAL):Validation of commercially available ELISA. Scand J Clin Lab Invest 70, 374-382.